EUCTR2004-000649-39-SE进行中（未招募）不适用
A randomized, controlled, multicenter, phase I/II study of cetuximab plus irinotecan investigating the pharmacodynamics, genomics and -genetics as well as the safety and efficacy of a dose escalation schedule of cetuximab compared with the standard fixed dosing regimen in patients with irinotecan-resistant EGFR expressing metastatic colorectal cancer. - EVEREST
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Merck KGaA
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically confirmed diagnosis of adenocarcinoma of the colon or rectum. Metastatic colorectal adenocarcinoma not suitable for curative-intent treatment. Presence of at least one bidimensionally measurable lesion, not in a previously irradiated area. Immunohistochemical evidence of EGFR expression prior to study entry in primary tumor and/or at least one metastasis. Irinotecan 180 mg/m2 (210mg/m² is accepted), either as monotherapy or in combination with other agents, every 2 weeks for at least six weeks as most recent chemotherapy treatment. Up to two prior licensed dosage attenuations below 180mg/m² for irinotecan-associated toxicity are permitted. Time between last treatment and progression on the irinotecan-based therapy should not be longer than 90 days. Documented progression according to modified WHO criteria by comparison of CT or MRI scans on/after the irinotecan based therapy (new lung lesions may be documented by chest x-ray) whereby the time between documentation of progression and start of study treatment should not be longer than 90 days. At least one tumor site suitable for biopsy sampling. Still being able to tolerate therapy with irinotecan. Karnofsky performance status of ³ 80 at study entry. Effective contraception for both male and female patients if risk of conception exists. Neutrophils = 1.5 x 109/L, platelets = 100 x 109/L, and hemoglobin = 9 g/dL. Bilirubin level either normal or < 1.5 x ULN, ASAT and ALAT = 2.5 x ULN (= 5 x ULN in case of liver metastasis) and serum creatinine < 1.5 x ULN. Recovered from relevant toxicities of previous chemotherapy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Brain metastasis (known or suspected). Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to study entry. Having participated in another study within the preceding 30 days.Concurrent chronic systemic immune therapy, chemotherapy, radiation therapy or hormone therapy not indicated in the study protocol. Any investigational agent within 4 weeks prior to entry. Having received mitomycin C within 6 weeks prior to study entry. Any active dermatological condition > Grade 1. Previous exposure to EGFR pathway targeting therapy. Having previously participated in a study which included a possibility of being allocated to cetuximab therapy (whether or not the patient actually received cetuximab). Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months or left ventricular ejection fraction (LVEF) below the institutional range of normal. Acute or subacute intestinal occlusion or history of inflammatory bowel disease. Known allergic/hypersensitivity reaction to any of the components of the treatment. Pregnancy (absence confirmed by serum/urine b-HCG) or breast-feeding. Other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix. Known drug abuse/ alcohol abuse. Legal incapacity or limited legal capacity medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.
研究者
相似试验
进行中（未招募）
不适用
A randomized, controlled, multicenter, phase I/II study of cetuximab plus irinotecan investigating the pharmacodynamics, genomics and -genetics as well as the safety and efficacy of a dose escalation schedule of cetuximab compared with the standard fixed dosing regimen in patients with irinotecan-resistant EGFR expressing metastatic colorectal cancer. - EVERESTEUCTR2004-000649-39-ATMerck KGaA160
进行中（未招募）
不适用
A randomized, controlled, multicenter, phase I/II study of cetuximab plus irinotecan investigating the pharmacodynamics, genomics and -genetics as well as the safety and efficacy of a dose escalation schedule of cetuximab compared with the standard fixed dosing regimen in patients with irinotecan-resistant EGFR expressing metastatic colorectal cancerMetastatic colorectal cancer refractory to irinotecan treatmentMedDRA version: 6.1Level: PTClassification code 10052358EUCTR2004-000649-39-ITMERCK S.P.A.
已完成
1 期
Study on the safety and efficacy of BIOCHAPERONE 1 in the treatment of diabetic foot ulcers.CTRI/2011/091/000202Virchow Biotech Pvt Ltd192
进行中（未招募）
不适用
A phase II, controlled, randomized, multicentre, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine with various doses of the AS03 adjuvant compared to Fluarix™ (GlaxoSmithKline Biologicals) administered intramuscularly in subjects aged 18-64 years. - FLU-LD-012Immunisation of healthy male and female subjects aged 18-64 years against influenzaEUCTR2007-003776-18-DEGlaxoSmithKline Biologicals1,000
进行中（未招募）
1 期
A phase II, controlled, randomized, multicentre, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine with various doses of the AS03 adjuvant compared to Fluarix™ (GlaxoSmithKline Biologicals) administered intramuscularly in subjects aged 18-64 years. - FLU-LD-012Immunisation of healthy male and female subjects aged 18-64 years against influenzaEUCTR2007-003776-18-FRGlaxoSmithKline Biologicals1,000